Idiopathic Inflammatory Myopathy Treatment Market Size, Share & Industry Analysis, By Disease Type (Dermatomyositis, Polymyositis, Necrotizing Autoimmune Myopathy, Others), By Treatment (Corticosteroids, Immunosuppressants, Others), By Route of Administration (Oral, Intravenous, Others), By Distribution Channel (Hospitals Pharmacies, Retail Pharmacies, Online Pharmacies, Others) and Regional Forecast, 2019-2032

The global idiopathic inflammatory myopathy treatment market size stood at USD 652.3 million in 2018 and is projected to reach USD 1,229.1 million by 2032, exhibiting a CAGR of 4.6% during the forecast period based on our analysis in the existing report.

Idiopathic inflammatory myopathies refers to a group of heterogeneous autoimmune disorders which affects a number of critical parts of the human body, including the skeletal muscles, lungs, joints, and skin. Owing to the increasing awareness regarding these critical diseases, there is a greater demand for effective and advanced therapeutics which are unmet. In earlier times, the diagnosis of dermatomyositis (DM) and polymyositis (PM) was challenging owing to the rarity of the diseases, the possibility of overlap syndromes, and the variations in the clinical presentation of the disorder. But increasing technological advancements in modern times are anticipated to bypass these limitations and factors as such are also anticipated to contribute to the global idiopathic inflammatory myopathy medications market growth.

In the current idiopathic inflammatory myopathies therapeutics market scenario, there are a number of factors and trends providing major impetus to the growth of these drugs. There is an increasing awareness with respect to the serious impacts of the various forms of myositis on human health. An increasing awareness of the disorder is further leading to a higher number of diagnostic testing, which in turn, is increasing the prevalence of the disorder, leading to its growth.

Request a Free sample to learn more about this report.

Individuals who develop idiopathic inflammatory myopathies are often at risk for the development of disabilities and if it is not administered effectively, then it may lead to death. Such factors have also contributed to the greater growth of the global market, despite rarity of the disease. Improved understanding of the disease, increasing research and development of novel therapeutics, and greater awareness have contributed substantially to the introduction of new myositis medications.

MARKET DRIVERS

“Increasing Awareness and Strong Pipeline Candidates Likely to Propel Growth”

One of the most crucial drivers for idiopathic inflammatory myopathies treatment market growth is the increasing awareness regarding the various forms of myositis and the corresponding increase in R&D leading to an anticipation in terms of new product launches. Idiopathic inflammatory myopathies therapeutics include a multi-faceted approach which may lead to the usage of several types of medications. A number of key market leaders are working towards regulatory approvals of new therapeutics. such as biologics, which are in the initial stages of clinical trials. For instance, a South Korean clinical stage pharmaceutical company called immunoforge has an important pipeline candidate for the treatment of polymyositis (PM) and inclusion body myositis (IBM). The pipeline candidate is called PF1801 and it is anticipated to boost the market growth.

“Emergence of Modern Therapies to Drive the Market Worldwide”

The emergence of new modern therapies and the increasing demand for more effective therapeutics are two of the significant factors driving the market growth. While the earlier and mainstay treatment were restricted to glucocorticoids and a range of immunosuppressants up to an extent, new therapeutic options have emerged for the treatment of a range of myositis. The need for modern therapies were especially apprehended during the treatment of the difficult-to-treat cases of idiopathic inflammatory myopathies, such as refractory cases of the disorder. This has led to the development of a huge unmet need for treatment in the market and it is anticipated to be one of the other key driving factors of the market growth.

SEGMENTATION

By Disease Type Analysis

“Polymyositis (PM) Segment to Grow Rapidly Owing to Rising Prevalence of This Myopathy”

On the basis of disease type, the market can be segmented into dermatomyositis (DM), polymyositis (PM), inclusion body myositis (IBM), necrotizing autoimmune myopathy (NAM), and others.

The polymyositis (PM) segment is estimated to hold a dominant idiopathic inflammatory myopathy treatment market share, especially owing to their status as the high occurring form of myositis and its ability to cause disability in individuals who do not seek timely medical intervention. This segment is anticipated to grow at the highest CAGR on account of the presence of high prevalence of this form of myopathy and its presence in a number of clinical pipeline of key market players.

To know how our report can help streamline your business, Speak to Analyst

Some of the other segments that have contributed to the steady growth of the market are dermatomyositis (DM), inclusion body myositis (IBM), and necrotizing autoimmune myopathy (NAM). In terms of strong pipeline candidates, inclusion body myositis (IBM) has a significant presence in the pipelines of some of the key market players. Dermatomyositis (DM) segment has the second largest market share, after the inclusion body myositis (IBM) segment.

By Treatment Analysis

“Immunosuppressants Segment to Lead: Increasing Patient Pool Will Favor Growth”

On the basis of treatment, the global market can be segmented into corticosteroids, immunosuppressants, intravenous immunoglobulins, and others. The immunosuppressants segment is anticipated to grow at a faster CAGR. This is primarily caused owing to the increasing usage of corticosteroids and the presence of a large number of patients across the world. Treatment through the usage of corticosteroids often have to be supplemented by immunosuppressants for providing an effective treatment and management of the disorder. This, coupled with the high cost of some of the immunosuppressants, are anticipated to contribute to the high growth rate of this segment. It is further set to augment the idiopathic inflammatory myopathies treatment market revenue in the coming years.

Owing to the increasing prevalence of various forms of myositis and the advanced and refractory nature of some of the cases, there is a greater administration of intravenous immunoglobulins. The expensiveness of intravenous immunoglobulins are also anticipated to contribute to its comparatively higher growth rate. Corticosteroids occupy the second highest market share, after the immunosuppressants because of its status as a mainstay treatment option.

By Route of Administration Analysis

“Intraveneous Segment to Hold the Highest Share Stoked by Intravenous Administration”

On the basis of route of administration, the market for idiopathic inflammatory myopathy therapeutics can be segmented into oral, intravenous, and others. The intravenous segment is anticipated to have the dominant share because these medications often consist of intravenous immunoglobulins and some immunosuppressants which can be administered intravenously and are often expensive. These factors further lead them to occupy a higher value share.

Oral segment is anticipated to hold the second largest share because they also consist of few of the important therapeutics, such as corticosteroids and immunosuppressants. These medications often form the first line of treatment and are also considered to be the mainstay therapeutics for the various forms of myositis.

By Distribution Channel Analysis

“Hospital Pharmacies Segment to Dominate Backed by Need for Trained Medical Professionals”

On the basis of distribution channel, the market for idiopathic inflammatory myopathies treatment can be segmented into hospital pharmacies, retail pharmacies, online pharmacies, and others. The hospital pharmacies segment is anticipated to acquire the dominant market share because intravenous immunoglobulins are administered by trained medical professionals in the cases of advanced and critical forms of idiopathic inflammatory myopathies. It is one of the most vital inflammatory myopathy medications market trends.

Retail pharmacies segment is anticipated to hold the second largest share because in the cases of re-filling prescriptions, these institutions are able to provide more efficient facilities, especially for corticosteroids and immunosuppressants. Online pharmacies segment is anticipated to experience the highest CAGR for revenue increase owing to the increasing usage of online pharmacy facilities, which are gaining popularity because of their ease and convenience.

REGIONAL ANALYSIS

North America generated a revenue of USD 312.4 million in 2018 and is anticipated to emerge dominant in the market during the forecast period. The high prevalence of various forms of myositis, coupled with the new product launches and high medical expenditure across the region, would expand the idiopathic inflammatory myopathy treatment market size in this region. Besides this, the increasing research and development initiatives with respect to emerging modern therapies, coupled with increasing awareness and technological advancements in diagnostics, are expected to drive the market in North America during the forecast period.

Asia Pacific is expected to witness the highest growth in the market value. Owing to the increasing disposable incomes across the region leading to higher healthcare expenditure, there is a greater awareness with respect to idiopathic inflammatory myopathies. Increasing prevalence of various forms of myositis from the key countries, such as Japan and the increasing adoption of advanced therapeutics for treatment are also anticipated to drive the idiopathic inflammatory myopathy therapeutics market growth across the region.

To get more information on the regional analysis of this market, Request a Free sample

On the other hand, Europe is projected to witness significant growth in the market because of the presence of several countries with high prevalence of idiopathic inflammatory myopathies. The high growth countries, including the Scandinavian countries such as Sweden, and other key countries such as Germany would contribute to the growth of the European market. In Latin America, the market for idiopathic inflammatory myopathy medications is anticipated to undergo a restricted growth as compared to the other regions. However, the increasing awareness in key regions such as Brazil which has formulated key guidelines for the treatment of myopathies will drive the growth in the future. The Middle East and Africa are expected to witness a more steady growth in the future on account of the rising prevalence and awareness of myositis.

INDUSTRY KEY PLAYERS

“Market Players to Focus on Research & Development for Gaining Regulatory Approvals”

The global idiopathic inflammatory myopathy drugs market is dominated by some of the key companies owing to their strong product portfolio, key strategic decisions, and dominance of market share. These include a group of 3 key companies with wider geographic presence and persistent R&D, resulting in strong regulatory approvals, especially in the case of intravenous immunoglobulins. In the same instance, a number of clinical stage pharmaceutical companies are also present in the market. These emerging competitors possess robust pipeline candidates which include biologics solely indicated for the treatment of the idiopathic inflammatory myopathies.

List Of Key Companies Profiled:

• immunoforge


• ORPHAZYME A/S


• Biotest AG


• CSL Limited (CSL Behring)


• Grifols, S.A.


• Kedrion S.p.A


• LFB Group


• Shire (Takeda Pharmaceutical Company Limited)


• Pfizer Inc.


• Mylan N.V.


• Others

KEY INDUSTRY DEVELOPMENTS:

• July 2021- Octapharma USA received the USFDA approval for Octagam 10% [Immune Globulin Intravenous (Human)], the first and only intravenous immunoglobulin (IVIg) to be indicated for the treatment of adult dermatomyositis, a rare immune-mediated inflammatory disease.


• May 2021 – Octapharma received the approval from European Union Octagam 10%, a human plasma-derived intravenous immunoglobulin (IVIg) for the treatment of dermatomyositis.


• March 2021 – Corbus Pharmaceuticals Holdings, Inc., a clinical-stage drug development company announced that the last subject completed the final visit in the double-blind, placebo-controlled part of the Company’s Phase 3 DETERMINE study of lenabasum for the treatment of dermatomyositis.


• October 2020 – Kezar Life Sciences, Inc., a clinical stage biotechnology company, announced that the USFDA has granted Orphan Drugs Designations (ODD) for KZR-616 for the treatment of polymyositis (PM) and dermatomyositis (DM)

REPORT COVERAGE

An Infographic Representation of Idiopathic Inflammatory Myopathy Treatment Market

View Full Infographic

To get information on various segments, share your queries with us

The increasing awareness of idiopathic inflammatory myopathies, increased prevalence of the disorder, strong pipeline candidates, and emerging modern therapies based on advanced technologies are expected to increase the global idiopathic inflammatory myopathies treatment market growth. 

To gain extensive insights into the market, Request for Customization

Along with this, the report provides an extensive analysis of the global market dynamics and competitive landscape and scenario. Various key insights presented in the report are the prevalence of idiopathic inflammatory myopathy by key countries, 2018, pipeline analysis, key industry developments, new product launches, and advancements in research & development of treatment options. Along with these, the other key insights include key strategies adopted by the market leaders, competitive landscape, and company profiles.

Report Scope & Segmentation